A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
GFH312 could be a novel therapeutic option in the acute/chronic inflammatory process of
atherosclerosis and provides potential beneficial effects to microvasculature function for
PAD patients with IC in addition to preventing ischemia-reperfusion injury. This phase II
study is designed to explore the clinical safety and efficacy of GFH312 after multiple oral
doses, to support further development in patients with PAD or other atherosclerotic diseases.